Symphogen

Servier signed a definitive agreement to acquire Symphogen, a leading antibody discovery company, to boost its antibody capabilities and leverage its R&D pipeline
AP
Fri, 04/3/20 - 12:27 pm
Servier
R&D
Symphogen
antibodies
Baxalta strikes a $1.6B immuno-oncology deal ahead of potential Shire deal
BioPharma Dive
Tue, 01/5/16 - 11:20 am
Baxalta
Shire
M&A
immuno-oncology
Symphogen
R&D
Merck KGaA abandons Symphogen's cancer drug ahead of Phase III
Fierce Biotech
Thu, 01/29/15 - 09:39 am
Merck KGaA
Symphogen
Sym004
Symphogen lines up record $131M venture round
Fierce Biotech
Fri, 01/7/11 - 07:24 am
Symphogen
venture capital